Earnings Releases·Nov 3, 2026, 4:03 PM ET

Mirum Pharmaceuticals — Third Quarter 2026 Earnings Summary

Total revenue reached $185.7 million, up from $133.0 million in Q3 2025, driven by 45% year-over-year growth in LIVMARLI® sales ($133.4 million) and 28% growth in Bile Acid Medicines ($52.3 million), though the company reported a net loss of $40.8 million compared to net income of $2.9 million in the prior year period.
Full-year 2026 net product sales guidance was increased to $715 million–$720 million, supported by the recent U.S. FDA approval and launch of ATEBRIOZ® and positive Phase 3 results for LIVMARLI (EXPAND) and brelovitug (AZURE-1).
The company repurchased $20.0 million of its 4.00% convertible senior subordinated notes due 2029, while total liabilities rose to $1,080.8 million and stockholders' equity shifted to a deficit of $54.2 million as of September 30, 2026.
Future outlook includes expected topline data for brelovitug in HDV (Q4 2026) and Volixibat in PBC (Q1 2027), with planned NDA submissions for Volixibat (PSC), LIVMARLI (sNDA), ATEBRIOZ (pediatric expansion), and brelovitug (BLA) targeted for H1 2027.